The recombinant unglycosylated single chain urokinase-type plasminogen activator saruplase is cleared for a large part by the liver. A large interindividual variation in saruplase concentration is found in acute myocardial infarction (AMI) patients. The variable cardiac performance after an infarct may induce differences in liver blood flow that could explain the concentration diversity. This study was performed to investigate the relation between hepatic blood flow and the pharmacokinetic and pharmacodynamic properties of saruplase.
Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction.
CHDR
van Griensven JM, Koster RW, Hopkins GR, Beier H, Günzler WA, Kroon R, Schoemaker RC, Cohen AF
